Literature DB >> 667861

Clinical spectrum of anthracycline antibiotic cardiotoxicity.

M R Bristow, M E Billingham, J W Mason, J R Daniels.   

Abstract

Anthracycline derivatives may produce early or late cardiotoxic reactions in man. Early effects include: (a) pericarditis-myocarditis which can affect patients with no previous history of cardiac disease and which carries a high mortality rate ( approximately 20%); (b) left ventricular dysfunction which may lead to clinically significant heart failure in patients with limited cardiac reserve; and (c) arrhythmias, the most common of which is sinus tachycardia. Symptomatic supraventriclar tachycardia, heart block, and ventricular arrhythmias can occur, however, and may reflect primary effects on cardiac muscle or the conduction system. Late effects of anthracyclines are directly related to the degree of associated myocyte damage and include subclinical left ventricular dysfunction and overt heart failure. The implications for prognosis and further treatment are discussed for each of these entities and a common pathogenetic mechanism is proposed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667861

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  52 in total

1.  Fluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity.

Authors:  Yang Liu; Chi Chen; Xiaoxiang Duan; Wenting Ma; Man Wang; Mengyi Tu; Ying Chen
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

2.  Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.

Authors:  Saisudha Koka; Rakesh C Kukreja
Journal:  Mol Cell Pharmacol       Date:  2010

3.  Daunorubicin, amsacrine, and sinus arrest.

Authors:  L A Kindman; J S Almenoff; V A Narurkar; K Blake
Journal:  West J Med       Date:  1991-04

Review 4.  Anthracyclines: cardiotoxicity and its prevention.

Authors:  J P Hale; I J Lewis
Journal:  Arch Dis Child       Date:  1994-11       Impact factor: 3.791

Review 5.  Doxorubicin-induced apoptosis: implications in cardiotoxicity.

Authors:  B Kalyanaraman; Joy Joseph; Shashi Kalivendi; Suwei Wang; Eugene Konorev; Srigiridhar Kotamraju
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

6.  P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.

Authors:  Wuqiang Zhu; Wenjun Zhang; Weinian Shou; Loren J Field
Journal:  Cardiovasc Res       Date:  2014-05-08       Impact factor: 10.787

7.  Cardiovascular autonomic function in anthracycline-treated breast cancer patients.

Authors:  M Viniegra; M Marchetti; M Losso; A Navigante; S Litovska; A Senderowicz; L Borghi; J Lebron; D Pujato; H Marrero
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Doxorubicin cardiotoxicity in African Americans.

Authors:  Syed Hasan; Kimberly Dinh; Fred Lombardo; John Kark
Journal:  J Natl Med Assoc       Date:  2004-02       Impact factor: 1.798

9.  Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q.

Authors:  Karunakaran Chandran; Deepika Aggarwal; Raymond Q Migrino; Joy Joseph; Donna McAllister; Eugene A Konorev; William E Antholine; Jacek Zielonka; Satish Srinivasan; Narayan G Avadhani; B Kalyanaraman
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

10.  Anticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts).

Authors:  R P Gehdoo
Journal:  Indian J Anaesth       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.